{"database": "lobbying", "table": "lobbying_activities", "rows": [[2513496, "7b03161e-3098-427c-8d32-7c86a2f0a96b", "Q3", "THE PETRIZZO GROUP, INC.", 305932, "CEL-SCI CORPORATION", 2020, "third_quarter", "MED", "Activity related to phase III clinical trial in head and neck cancer to boost the immune system before the ravages of surgery, radiation and chemotherapy. The Phase III trial is the largest ever in head and neck cancer with 928 patients enrolled. \nLEAPS COVID-19 Immunotherapyas a new immune-based treatment for COVID-19", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Vice President of the U.S.", 50000, null, 0, 0, "2020-10-18T13:02:58.370000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2513496"], "units": {}, "query_ms": 0.41544483974575996, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}